Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1363-1376.doi: 10.12092/j.issn.1009-2501.2026.10.007
Qiu FANG1,2(
), Shuangmiao JIANG1, Jing WANG3, Xuemei LUO3, Lu JIN3, Huaijun ZHU1,3,4,*(
)
Received:2025-09-25
Revised:2025-11-13
Online:2026-10-26
Published:2026-11-11
Contact:
Huaijun ZHU
E-mail:fangqiu5027@163.com;huaijun.zhu@gmail.com
CLC Number:
Qiu FANG, Shuangmiao JIANG, Jing WANG, Xuemei LUO, Lu JIN, Huaijun ZHU. External validation of population pharmacokinetic models for linezolid in adult patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1363-1376.
| Characteristic | Values |
| Sex (M/F) | 77/34 |
| Age (years) | 63.27±16.54 |
| Weight (kg) | 65.41±12.89 |
| Single dose (mg) | 600 (400-600) |
| Concentrations (μg/mL) | 5.5 (0.3-26.7) |
| CRRT [n(%)] | 18 (16.22%) |
| Rifampin [n(%)] | 1 (0.90%) |
| ICU [n(%)] | 56 (50.45%) |
| ALT (U/L) | 23.9 (2-508.3) |
| ALB (g/L) | 33.27±4.84 |
| SCR (μmol/L) | 73 (20-912) |
| eGFR [mL/(min·1.73 m2)] | 98.5 (6.4-428) |
| UA (μmol/L) | 256.19 (71- |
| WBC (109/L) | 10 (0.4-33.1) |
| HGB (g/L) | 104 (67-155) |
| PLT (109/L) | 208 (70-546) |
| CrCL (mL/min) | 58.61(45.20-122.84) |
Table 1 Main characteristics of patients (n=111)
| Characteristic | Values |
| Sex (M/F) | 77/34 |
| Age (years) | 63.27±16.54 |
| Weight (kg) | 65.41±12.89 |
| Single dose (mg) | 600 (400-600) |
| Concentrations (μg/mL) | 5.5 (0.3-26.7) |
| CRRT [n(%)] | 18 (16.22%) |
| Rifampin [n(%)] | 1 (0.90%) |
| ICU [n(%)] | 56 (50.45%) |
| ALT (U/L) | 23.9 (2-508.3) |
| ALB (g/L) | 33.27±4.84 |
| SCR (μmol/L) | 73 (20-912) |
| eGFR [mL/(min·1.73 m2)] | 98.5 (6.4-428) |
| UA (μmol/L) | 256.19 (71- |
| WBC (109/L) | 10 (0.4-33.1) |
| HGB (g/L) | 104 (67-155) |
| PLT (109/L) | 208 (70-546) |
| CrCL (mL/min) | 58.61(45.20-122.84) |
| Model | Study | Year | n | Route | Software | CMT | Retained covariates | Fixed effect parameters | BSV* | RUV# |
| Model1 | Whitehouse[ | 2005 | 28 | IV | NONMEM | 2 | CL: WT V1: WT | CL (L/h) = V2 (L)=240 Q (L/h) =7.48 | CL=0.231 V1= V2=2.132 | Prob= Add=5.476 |
| Model2 | Plock[ | 2007 | 34 | PO/IV | NONMEM | 2 | — | CL (L/h) =11.1 V1 (L) = 20 V2 (L) =28.9 Q (L / h) =75 RCLF=0.764 KIC= | CL=0.174 V2=0.161 V3=0.121 RCLF=0.118 | Prob=0.008 Add= |
| Model3 | Abe[ | 2009 | 455 | PO/IV | NONMEM | 1 | CL: WT, AGE V: WT | CL (L/h) = 1.28× (WT/69.5)1.91 + V (L) =47.0× (WT/69.5)0.903 | CL=0.217 V= | Prob= |
| Model4 | Zhang[ | 2011 | 31 | IV | Phoenix NLME | 2 | V2: WT | CL (L/h) =7.99 V1 (L) =26.99 V2 (L) =22.22+ 0.617×(WT-66) Q (L/h) =101.28 | CL= 0.054 V1= V2= Q= | Prob= |
| Model5 | Zhang[ | 2011 | 57 | PO/IV | Phoenix NLME | 1 | CL: WT, AGE V: WT | CL (L/h) =4.70+ V (L) = 38.85+ 0.790×(WT-60) | CL= V= | Prob= |
| Model6 | Tsuji[ | 2013 | 14 | IV | NONMEM | 1 | CL: eGFR,WT, HGB, ALT V: WT | CL (L/h) = V (L) = 1.310×WT | CL=0.098 V=0.115 | Prob=0.047 |
| Model7 | Matsumoto[ | 2014 | 44 | PO/IV | NONMEM | 1 | CL: CrCL | CL (L/h) = V (L) = 27.6 | CL= | Prob= |
| Model8 | Boak[ | 2014 | 41 | PO/IV | S-ADAPT | 1 | CL: WT, eGFR V: WT | CL (L/h) = (WT/65)0.75×(eGFR/120×2.17 +4.55) V (L) =(WT/65)× 44.3 | CL=0.239 V= | Prob=0.051 Add=0.309 |
| Model9 | T?pper[ | 2016 | 20 | IV | NONMEM | 1 | — | CL (L/h) =5.71 V (L) = 41.1 | CL=0.775 V=0.253 | Prob= Add=0.347 |
| Model10 | Tsuji[ | 2017 | 81 | IV | NONMEM | 2 | CL: Age, CrCL, WT V1: WT V2: WT Q: WT | CL (L/h) =(1.86× e? 1.44×(CrCL/100)× (WT/70)0.75 V1 (L) =22.9× (WT/70) V2 (L) =24.7×(WT/70) Q (L/h) =10.9× (WT/70)0.75 | CL= 0.136 V1=2.019 V2= Q=3.320 | Prob=0.101 Add=0.063 |
| Model11 | Ide[ | 2018 | 27 | IV | NONMEM | 2 | — | CLpreserved (L/h) =6.36 CLdysfunction(L/h) = 2.06 CLCRRT(L/h) =2.74 V1 (L) =19.6 V2 (L) =22.4 Q (L/h) =26.4 | CLp=0.448 CLd=0.161 CLc=0.308 V1=0.323 V2=0.123 Q=0.194 | Prob= |
| Model12 | Xie[ | 2019 | 15 | IV | NONMEM | 2 | CL: Age, WT V1: WT V2: WT Q: WT | CL (L/h) = 7.8×(1- V1 (L) = 14.3× (WT/70);V2(L)=23.8×(WT/ 70) Q (L/h) =65.1× (WT/70)0.75 | CL= 0.370 V1=0.173 BR=0.965 | Prob= |
| Model13 | Dong[ | 2019 | 27 | IV | NONMEM | 1 | CL: AGE | CL (L/h) = 6.8× (1+ V (L) = 78.6 | CL= V=0.135 | Prob= Add=0.227 |
| Model14 | Wang[ | 2019 | 37 | IV | NONMEM | 1 | CL: PLT | CL (L/h) = 11.8× (PLT/200)0.261 V (L) =209 | CL= V= | Prob=1.040 |
| Model15 | Wang[ | 2021 | 117 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) = 5.60× (CrCL/61)0.386 V (L) = 43.4 | CL=0.408 V=0.031 | Prob=0.131 Add= |
| Model16 | Fang[ | 2021 | 152 | PO/IV | NONMEM | 1 | CL: CrCL,WBC V: ALB | CL (L/h) = 3.07+ 2.37×(CrCL/73)+ 0.559×(WBC/9.63) V (L) = 93.1-1.33× ALB | CL= V=0.107 | Prob= |
| Model17 | Wicha[ | 2022 | 120 | IV | NONMEM | 1 | CL: CrCL,WT | CL (L/h) = 6.82× (1+ (WT/75)0.75 V (L) =40× (WT/75) | CL=0.279 | Prob=0.087 |
| Model18 | Wu[ | 2022 | 83 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) =3.66+ 2.18×CrCL/65.38 V (L) = 54 | CL=0.123 | Prob= |
| Model19 | Bock[ | 2023 | 62 | PO/IV | Monolix | 1 | CL: RIF, WT V: WT | CL (L/h) = 2.81× (WT/70)0.75×2.50RIF V (L) = 30.4× (WT/70)1.0 | CL=0.502 V=0.32 | Prob= Add=2.434 |
| Model20 | Liu[ | 2023 | 69 | IV | NONMEM | 2 | CL: CrCL,WT | CL (L/h) = 4.11× (1+1.6)×(1+(WT-79)×0.02) V1 (L) = 37.4×(1-0.277) V2 (L) =15.5 Q (L/h) =10.5 | CL=0.273 V1= | Prob= Add=2.102 |
| Model21 | Bock[ | 2023 | 91 | PO/IV | — | 1 | — | CL (L/h) = 3.5 V (L) = 37.9 | CL=0.434 V=0.130 | Prob=0.08 Add=1.32 |
| Model22 | Li[ | 2024 | 120 | IV | NONMEM | 1 | CL: UA | CL (L/h) = 4.22× e(- V (L) = 45.8 | CL=0.155 | Add=4.63 |
| Model23 | Xu[ | 2024 | 166 | IV | NONMEM | 1 | CL: Age, CrCL | CL (L/h) = 2.7× (AGE/82)?0.56× (CrCL/42.0)0.50 V (L) = 57.1 | CL=0.1 | Add=11.56 |
| Model24 | Milakovi′c[ | 2024 | 9 | IV | NONMEM | 1 | — | CL (L/h) = 5.9 V (L) = 41.1 | CL= V=0.132 | Prob= |
| Model25 | Maha[ | 2025 | 59 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) = 3.72×(1+ V (L) = 36.9 | CL=0.135 V=0.278 | Prob= |
Table 2 Basic information of published LZD PPK models
| Model | Study | Year | n | Route | Software | CMT | Retained covariates | Fixed effect parameters | BSV* | RUV# |
| Model1 | Whitehouse[ | 2005 | 28 | IV | NONMEM | 2 | CL: WT V1: WT | CL (L/h) = V2 (L)=240 Q (L/h) =7.48 | CL=0.231 V1= V2=2.132 | Prob= Add=5.476 |
| Model2 | Plock[ | 2007 | 34 | PO/IV | NONMEM | 2 | — | CL (L/h) =11.1 V1 (L) = 20 V2 (L) =28.9 Q (L / h) =75 RCLF=0.764 KIC= | CL=0.174 V2=0.161 V3=0.121 RCLF=0.118 | Prob=0.008 Add= |
| Model3 | Abe[ | 2009 | 455 | PO/IV | NONMEM | 1 | CL: WT, AGE V: WT | CL (L/h) = 1.28× (WT/69.5)1.91 + V (L) =47.0× (WT/69.5)0.903 | CL=0.217 V= | Prob= |
| Model4 | Zhang[ | 2011 | 31 | IV | Phoenix NLME | 2 | V2: WT | CL (L/h) =7.99 V1 (L) =26.99 V2 (L) =22.22+ 0.617×(WT-66) Q (L/h) =101.28 | CL= 0.054 V1= V2= Q= | Prob= |
| Model5 | Zhang[ | 2011 | 57 | PO/IV | Phoenix NLME | 1 | CL: WT, AGE V: WT | CL (L/h) =4.70+ V (L) = 38.85+ 0.790×(WT-60) | CL= V= | Prob= |
| Model6 | Tsuji[ | 2013 | 14 | IV | NONMEM | 1 | CL: eGFR,WT, HGB, ALT V: WT | CL (L/h) = V (L) = 1.310×WT | CL=0.098 V=0.115 | Prob=0.047 |
| Model7 | Matsumoto[ | 2014 | 44 | PO/IV | NONMEM | 1 | CL: CrCL | CL (L/h) = V (L) = 27.6 | CL= | Prob= |
| Model8 | Boak[ | 2014 | 41 | PO/IV | S-ADAPT | 1 | CL: WT, eGFR V: WT | CL (L/h) = (WT/65)0.75×(eGFR/120×2.17 +4.55) V (L) =(WT/65)× 44.3 | CL=0.239 V= | Prob=0.051 Add=0.309 |
| Model9 | T?pper[ | 2016 | 20 | IV | NONMEM | 1 | — | CL (L/h) =5.71 V (L) = 41.1 | CL=0.775 V=0.253 | Prob= Add=0.347 |
| Model10 | Tsuji[ | 2017 | 81 | IV | NONMEM | 2 | CL: Age, CrCL, WT V1: WT V2: WT Q: WT | CL (L/h) =(1.86× e? 1.44×(CrCL/100)× (WT/70)0.75 V1 (L) =22.9× (WT/70) V2 (L) =24.7×(WT/70) Q (L/h) =10.9× (WT/70)0.75 | CL= 0.136 V1=2.019 V2= Q=3.320 | Prob=0.101 Add=0.063 |
| Model11 | Ide[ | 2018 | 27 | IV | NONMEM | 2 | — | CLpreserved (L/h) =6.36 CLdysfunction(L/h) = 2.06 CLCRRT(L/h) =2.74 V1 (L) =19.6 V2 (L) =22.4 Q (L/h) =26.4 | CLp=0.448 CLd=0.161 CLc=0.308 V1=0.323 V2=0.123 Q=0.194 | Prob= |
| Model12 | Xie[ | 2019 | 15 | IV | NONMEM | 2 | CL: Age, WT V1: WT V2: WT Q: WT | CL (L/h) = 7.8×(1- V1 (L) = 14.3× (WT/70);V2(L)=23.8×(WT/ 70) Q (L/h) =65.1× (WT/70)0.75 | CL= 0.370 V1=0.173 BR=0.965 | Prob= |
| Model13 | Dong[ | 2019 | 27 | IV | NONMEM | 1 | CL: AGE | CL (L/h) = 6.8× (1+ V (L) = 78.6 | CL= V=0.135 | Prob= Add=0.227 |
| Model14 | Wang[ | 2019 | 37 | IV | NONMEM | 1 | CL: PLT | CL (L/h) = 11.8× (PLT/200)0.261 V (L) =209 | CL= V= | Prob=1.040 |
| Model15 | Wang[ | 2021 | 117 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) = 5.60× (CrCL/61)0.386 V (L) = 43.4 | CL=0.408 V=0.031 | Prob=0.131 Add= |
| Model16 | Fang[ | 2021 | 152 | PO/IV | NONMEM | 1 | CL: CrCL,WBC V: ALB | CL (L/h) = 3.07+ 2.37×(CrCL/73)+ 0.559×(WBC/9.63) V (L) = 93.1-1.33× ALB | CL= V=0.107 | Prob= |
| Model17 | Wicha[ | 2022 | 120 | IV | NONMEM | 1 | CL: CrCL,WT | CL (L/h) = 6.82× (1+ (WT/75)0.75 V (L) =40× (WT/75) | CL=0.279 | Prob=0.087 |
| Model18 | Wu[ | 2022 | 83 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) =3.66+ 2.18×CrCL/65.38 V (L) = 54 | CL=0.123 | Prob= |
| Model19 | Bock[ | 2023 | 62 | PO/IV | Monolix | 1 | CL: RIF, WT V: WT | CL (L/h) = 2.81× (WT/70)0.75×2.50RIF V (L) = 30.4× (WT/70)1.0 | CL=0.502 V=0.32 | Prob= Add=2.434 |
| Model20 | Liu[ | 2023 | 69 | IV | NONMEM | 2 | CL: CrCL,WT | CL (L/h) = 4.11× (1+1.6)×(1+(WT-79)×0.02) V1 (L) = 37.4×(1-0.277) V2 (L) =15.5 Q (L/h) =10.5 | CL=0.273 V1= | Prob= Add=2.102 |
| Model21 | Bock[ | 2023 | 91 | PO/IV | — | 1 | — | CL (L/h) = 3.5 V (L) = 37.9 | CL=0.434 V=0.130 | Prob=0.08 Add=1.32 |
| Model22 | Li[ | 2024 | 120 | IV | NONMEM | 1 | CL: UA | CL (L/h) = 4.22× e(- V (L) = 45.8 | CL=0.155 | Add=4.63 |
| Model23 | Xu[ | 2024 | 166 | IV | NONMEM | 1 | CL: Age, CrCL | CL (L/h) = 2.7× (AGE/82)?0.56× (CrCL/42.0)0.50 V (L) = 57.1 | CL=0.1 | Add=11.56 |
| Model24 | Milakovi′c[ | 2024 | 9 | IV | NONMEM | 1 | — | CL (L/h) = 5.9 V (L) = 41.1 | CL= V=0.132 | Prob= |
| Model25 | Maha[ | 2025 | 59 | IV | NONMEM | 1 | CL: CrCL | CL (L/h) = 3.72×(1+ V (L) = 36.9 | CL=0.135 V=0.278 | Prob= |
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 | IF30 (%) |
| Model1 | 25.85 | 58.43 | 17.94 | 26.46 | 8.84 | 21.17 | 48.43 | 62.78 |
| Model2 | 46.99 | 68.63 | 17.49 | 26.46 | ?0.23 | 10.94 | 65.02 | 74.44 |
| Model3 | ?38.34 | 57.48 | 17.04 | 22.87 | 0.04 | 15.06 | 56.95 | 71.75 |
| Model4 | ?65.53 | 71.67 | 8.97 | 11.21 | ?12.59 | 21.68 | 43.50 | 70.40 |
| Model5 | ?8.41 | 52.39 | 17.94 | 27.35 | 0.91 | 15.24 | 62.78 | 78.92 |
| Model6 | ?78.74 | 79.48 | 3.14 | 5.83 | ?0.14 | 7.57 | 70.40 | 80.27 |
| Model7 | ?16.21 | 49.66 | 17.94 | 27.80 | 2.48 | 19.02 | 51.12 | 67.26 |
| Model8 | ?44.34 | 57.81 | 15.70 | 23.77 | ?5.57 | 16.42 | 56.95 | 78.48 |
| Model9 | ?41.21 | 59.22 | 13.45 | 20.63 | ?2.60 | 11.07 | 65.92 | 79.37 |
| Model10 | 61.36 | 72.78 | 17.49 | 22.87 | ?1.53 | 13.50 | 61.88 | 81.61 |
| Model11 | ?1.15 | 62.87 | 13.00 | 24.22 | 0.07 | 6.64 | 70.40 | 80.72 |
| Model12 | ?31.85 | 76.52 | 11.66 | 17.94 | ?5.11 | 47.61 | 17.04 | 24.66 |
| Model13 | ?36.47 | 61.82 | 13.45 | 19.73 | 0.04 | 8.96 | 72.20 | 81.17 |
| Model14 | ?57.17 | 63.76 | 10.76 | 15.70 | ?42.57 | 47.70 | 14.80 | 26.46 |
| Model15 | ?36.47 | 55.77 | 17.04 | 26.01 | ?10.23 | 17.32 | 57.40 | 78.03 |
| Model16 | ?40.44 | 52.94 | 17.49 | 25.56 | ?2.94 | 13.58 | 65.47 | 81.61 |
| Model17 | ?22.22 | 51.81 | 16.59 | 26.46 | ?5.79 | 17.26 | 60.09 | 78.48 |
| Model18 | ?38.34 | 54.15 | 17.04 | 22.87 | ?3.85 | 16.12 | 60.09 | 78.48 |
| Model19 | 58.92 | 63.26 | 23.32 | 30.49 | 1.63 | 14.58 | 60.09 | 71.75 |
| Model20 | ?65.34 | 71.24 | 7.62 | 13.90 | ?10.36 | 19.51 | 52.02 | 73.99 |
| Model21 | 19.08 | 49.25 | 23.32 | 32.29 | ?2.46 | 16.85 | 56.05 | 74.44 |
| Model22 | ?3.84 | 49.32 | 16.14 | 27.35 | 6.04 | 18.83 | 51.12 | 62.33 |
| Model23 | 32.62 | 59.35 | 17.94 | 27.35 | 12.57 | 32.28 | 34.08 | 47.53 |
| Model24 | ?48.78 | 61.35 | 11.21 | 18.83 | ?1.55 | 16.38 | 57.85 | 72.20 |
| Model25 | 40.81 | 60.31 | 22.42 | 32.29 | 5.97 | 19.35 | 51.12 | 67.71 |
Table 3 Prediction errors of LZD PPK models
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 | IF30 (%) |
| Model1 | 25.85 | 58.43 | 17.94 | 26.46 | 8.84 | 21.17 | 48.43 | 62.78 |
| Model2 | 46.99 | 68.63 | 17.49 | 26.46 | ?0.23 | 10.94 | 65.02 | 74.44 |
| Model3 | ?38.34 | 57.48 | 17.04 | 22.87 | 0.04 | 15.06 | 56.95 | 71.75 |
| Model4 | ?65.53 | 71.67 | 8.97 | 11.21 | ?12.59 | 21.68 | 43.50 | 70.40 |
| Model5 | ?8.41 | 52.39 | 17.94 | 27.35 | 0.91 | 15.24 | 62.78 | 78.92 |
| Model6 | ?78.74 | 79.48 | 3.14 | 5.83 | ?0.14 | 7.57 | 70.40 | 80.27 |
| Model7 | ?16.21 | 49.66 | 17.94 | 27.80 | 2.48 | 19.02 | 51.12 | 67.26 |
| Model8 | ?44.34 | 57.81 | 15.70 | 23.77 | ?5.57 | 16.42 | 56.95 | 78.48 |
| Model9 | ?41.21 | 59.22 | 13.45 | 20.63 | ?2.60 | 11.07 | 65.92 | 79.37 |
| Model10 | 61.36 | 72.78 | 17.49 | 22.87 | ?1.53 | 13.50 | 61.88 | 81.61 |
| Model11 | ?1.15 | 62.87 | 13.00 | 24.22 | 0.07 | 6.64 | 70.40 | 80.72 |
| Model12 | ?31.85 | 76.52 | 11.66 | 17.94 | ?5.11 | 47.61 | 17.04 | 24.66 |
| Model13 | ?36.47 | 61.82 | 13.45 | 19.73 | 0.04 | 8.96 | 72.20 | 81.17 |
| Model14 | ?57.17 | 63.76 | 10.76 | 15.70 | ?42.57 | 47.70 | 14.80 | 26.46 |
| Model15 | ?36.47 | 55.77 | 17.04 | 26.01 | ?10.23 | 17.32 | 57.40 | 78.03 |
| Model16 | ?40.44 | 52.94 | 17.49 | 25.56 | ?2.94 | 13.58 | 65.47 | 81.61 |
| Model17 | ?22.22 | 51.81 | 16.59 | 26.46 | ?5.79 | 17.26 | 60.09 | 78.48 |
| Model18 | ?38.34 | 54.15 | 17.04 | 22.87 | ?3.85 | 16.12 | 60.09 | 78.48 |
| Model19 | 58.92 | 63.26 | 23.32 | 30.49 | 1.63 | 14.58 | 60.09 | 71.75 |
| Model20 | ?65.34 | 71.24 | 7.62 | 13.90 | ?10.36 | 19.51 | 52.02 | 73.99 |
| Model21 | 19.08 | 49.25 | 23.32 | 32.29 | ?2.46 | 16.85 | 56.05 | 74.44 |
| Model22 | ?3.84 | 49.32 | 16.14 | 27.35 | 6.04 | 18.83 | 51.12 | 62.33 |
| Model23 | 32.62 | 59.35 | 17.94 | 27.35 | 12.57 | 32.28 | 34.08 | 47.53 |
| Model24 | ?48.78 | 61.35 | 11.21 | 18.83 | ?1.55 | 16.38 | 57.85 | 72.20 |
| Model25 | 40.81 | 60.31 | 22.42 | 32.29 | 5.97 | 19.35 | 51.12 | 67.71 |
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 (%) | IF30 (%) |
| Model11 | 87.41 | 87.41 | 21.21 | 33.33 | 0.81 | 10.18 | 66.67 | 81.82 |
| Model20 | ?77.56 | 77.56 | 0 | 3.03 | ?14.67 | 17.93 | 57.58 | 72.73 |
Table 4 Prediction errors of different models for 18 patients in the CRRT group
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 (%) | IF30 (%) |
| Model11 | 87.41 | 87.41 | 21.21 | 33.33 | 0.81 | 10.18 | 66.67 | 81.82 |
| Model20 | ?77.56 | 77.56 | 0 | 3.03 | ?14.67 | 17.93 | 57.58 | 72.73 |
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 (%) | IF30 (%) |
| Model1 | 29.42 | 59.33 | 17.89 | 25.79 | 11.94 | 21.37 | 47.89 | 61.58 |
| Model2 | 50.55 | 71.52 | 17.89 | 26.32 | ?0.20 | 11.42 | 64.21 | 74.21 |
| Model3 | ?38.76 | 59.37 | 15.26 | 22.11 | 0.06 | 15.62 | 56.32 | 70.53 |
| Model4 | ?64.46 | 72.92 | 8.95 | 10.53 | ?12.39 | 21.48 | 44.74 | 70.00 |
| Model5 | ?10.98 | 53.05 | 16.84 | 25.26 | 1.23 | 15.89 | 62.11 | 78.95 |
| Model7 | ?22.86 | 49.69 | 18.95 | 27.89 | 1.50 | 19.82 | 50.53 | 67.37 |
| Model8 | ?47.27 | 58.74 | 14.74 | 22.63 | ?5.65 | 17.25 | 54.21 | 77.89 |
| Model9 | ?38.93 | 60.61 | 12.11 | 20.00 | ?2.36 | 11.25 | 66.32 | 79.47 |
| Model10 | 52.61 | 64.72 | 17.37 | 22.63 | ?2.36 | 15.20 | 60.53 | 81.05 |
| Model11 | ?22.00 | 60.86 | 11.58 | 22.63 | 0.04 | 6.09 | 71.05 | 80.53 |
| Model13 | ?32.62 | 65.32 | 13.16 | 20.53 | 0.32 | 9.61 | 72.63 | 82.11 |
| Model14 | ?57.62 | 64.68 | 10.53 | 15.79 | ?42.66 | 49.39 | 15.26 | 26.84 |
| Model16 | ?42.75 | 56.83 | 15.79 | 22.63 | ?3.24 | 14.79 | 63.16 | 80.53 |
| Model18 | ?41.46 | 54.81 | 16.32 | 22.63 | ?3.77 | 17.20 | 58.42 | 77.89 |
| Model19 | 60.28 | 64.93 | 23.68 | 30.00 | 1.59 | 14.76 | 58.95 | 71.05 |
| Model21 | 18.16 | 49.91 | 23.68 | 31.05 | ?2.46 | 17.34 | 54.21 | 73.68 |
| Model22 | ?3.44 | 49.60 | 15.26 | 25.26 | 6.87 | 19.99 | 50.00 | 60.53 |
| Model23 | 17.88 | 55.46 | 18.95 | 28.95 | 10.13 | 31.84 | 34.21 | 48.42 |
| Model25 | 30.61 | 55.46 | 22.63 | 32.63 | 5.27 | 19.24 | 51.58 | 67.89 |
Table 5 Prediction errors of different models for 93 patients in the Non-CRRT group
| Model | MDPE (%) | MAPE (%) | F20 (%) | F30 (%) | MDIPE (%) | MAIPE (%) | IF20 (%) | IF30 (%) |
| Model1 | 29.42 | 59.33 | 17.89 | 25.79 | 11.94 | 21.37 | 47.89 | 61.58 |
| Model2 | 50.55 | 71.52 | 17.89 | 26.32 | ?0.20 | 11.42 | 64.21 | 74.21 |
| Model3 | ?38.76 | 59.37 | 15.26 | 22.11 | 0.06 | 15.62 | 56.32 | 70.53 |
| Model4 | ?64.46 | 72.92 | 8.95 | 10.53 | ?12.39 | 21.48 | 44.74 | 70.00 |
| Model5 | ?10.98 | 53.05 | 16.84 | 25.26 | 1.23 | 15.89 | 62.11 | 78.95 |
| Model7 | ?22.86 | 49.69 | 18.95 | 27.89 | 1.50 | 19.82 | 50.53 | 67.37 |
| Model8 | ?47.27 | 58.74 | 14.74 | 22.63 | ?5.65 | 17.25 | 54.21 | 77.89 |
| Model9 | ?38.93 | 60.61 | 12.11 | 20.00 | ?2.36 | 11.25 | 66.32 | 79.47 |
| Model10 | 52.61 | 64.72 | 17.37 | 22.63 | ?2.36 | 15.20 | 60.53 | 81.05 |
| Model11 | ?22.00 | 60.86 | 11.58 | 22.63 | 0.04 | 6.09 | 71.05 | 80.53 |
| Model13 | ?32.62 | 65.32 | 13.16 | 20.53 | 0.32 | 9.61 | 72.63 | 82.11 |
| Model14 | ?57.62 | 64.68 | 10.53 | 15.79 | ?42.66 | 49.39 | 15.26 | 26.84 |
| Model16 | ?42.75 | 56.83 | 15.79 | 22.63 | ?3.24 | 14.79 | 63.16 | 80.53 |
| Model18 | ?41.46 | 54.81 | 16.32 | 22.63 | ?3.77 | 17.20 | 58.42 | 77.89 |
| Model19 | 60.28 | 64.93 | 23.68 | 30.00 | 1.59 | 14.76 | 58.95 | 71.05 |
| Model21 | 18.16 | 49.91 | 23.68 | 31.05 | ?2.46 | 17.34 | 54.21 | 73.68 |
| Model22 | ?3.44 | 49.60 | 15.26 | 25.26 | 6.87 | 19.99 | 50.00 | 60.53 |
| Model23 | 17.88 | 55.46 | 18.95 | 28.95 | 10.13 | 31.84 | 34.21 | 48.42 |
| Model25 | 30.61 | 55.46 | 22.63 | 32.63 | 5.27 | 19.24 | 51.58 | 67.89 |
Fig.1 Goodness -of -fit graphs for some LZD PPK models A-C: DV-PRED scatter plot. D-F: DV-IPRED scatter plot. The solid black line is the line of identity (observed = predicted); the red dotted line is the trend line.
Fig.2 Boxplots of the prediction error with different models A: population prediction error boxplots. B: individual prediction error boxplots. The solid line in the box represents the median, the black dashed line and the pink dashed line represent the 0 and ±30 reference lines, respectively.
Fig.3 Visual predicted check result for some LZD PPK models Black solid dots represent observed concentrations, the top, middle and bottom three curves represent the 95th, 50th and 5th percentile of observed concentration, respectively, the three shaded areas represent 95% confidence intervals for the 95th, 50th and 5th percentiles of the simulated concentration, respectively.
| 1 | Clemett D, Markham A. Linezolid [J]. Drugs, 2000, 59(4): 815-27; discussion 28. |
| 2 |
邢贞建, 李祥, 江慧贤, 等. 应用蒙特卡洛模拟评价中国成人耐多药结核患者利奈唑胺给药方案[J]. 实用医学杂志, 2020, 36 (16): 2216- 2219.
doi: 10.3969/j.issn.1006-5725.2020.16.009 |
| 3 | Consensus on linezolid in the treatment of tuberculosis(2022 update)] [J]. Zhonghua Jie He He Hu Xi Za Zhi, 2022, 45(10): 988-995. |
| 4 |
Beringer P, Nguyen M, Hoem N, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings[J]. Antimicrob Agents Chemother, 2005, 49 (9): 3676- 3681.
doi: 10.1128/AAC.49.9.3676-3681.2005 |
| 5 |
Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability[J]. Biopharm Drug Dispos, 2001, 22 (3): 91- 97.
doi: 10.1002/bdd.255 |
| 6 |
Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid[J]. Front Public Health, 2022, 10, 967311.
doi: 10.3389/fpubh.2022.967311 |
| 7 |
Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients[J]. J Antimicrob Chemother, 2012, 67 (8): 2034- 2042.
doi: 10.1093/jac/dks153 |
| 8 |
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data[J]. J Pharmacokinet Biopharm, 1977, 5 (5): 445- 79.
doi: 10.1007/BF01061728 |
| 9 | Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'[J]. Kidney Int, 2013, 84 (3): 622- 623. |
| 10 |
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine[J]. Nephron, 1976, 16 (1): 31- 41.
doi: 10.1159/000180580 |
| 11 |
Cai X, Li R, Sheng C, et al. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients[J]. Eur J Pharm Sci, 2020, 145, 105237.
doi: 10.1016/j.ejps.2020.105237 |
| 12 |
Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill[J]. J Antimicrob Chemother, 2005, 55 (3): 333- 340.
doi: 10.1093/jac/dki014 |
| 13 |
Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthyvolunteers and septic patients[J]. Drug Metab Dispos, 2007, 35 (10): 1816- 1823.
doi: 10.1124/dmd.106.013755 |
| 14 |
Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients[J]. J Clin Pharmacol, 2009, 49 (9): 1071- 1078.
doi: 10.1177/0091270009337947 |
| 15 | 张雷. 利奈唑胺在中国人群的群体药代/药效动力学研究 [D]. 北京: 解放军医学院, 2011. |
| 16 |
Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction[J]. J Clin Pharmacol, 2013, 53 (9): 967- 973.
doi: 10.1002/jcph.133 |
| 17 |
Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients[J]. Int J Antimicrob Agents, 2014, 44 (3): 242- 247.
doi: 10.1016/j.ijantimicag.2014.05.010 |
| 18 |
Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid[J]. Antimicrob Agents Chemother, 2014, 58 (4): 2334- 2343.
doi: 10.1128/AAC.01885-13 |
| 19 |
Töpper C, Steinbach CL, Dorn C, et al. Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions[J]. Ther Drug Monit, 2016, 38 (5): 573- 578.
doi: 10.1097/FTD.0000000000000324 |
| 20 |
Tsuji Y, Holford NHG, Kasai H, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients[J]. Br J Clin Pharmacol, 2017, 83 (8): 1758- 1772.
doi: 10.1111/bcp.13262 |
| 21 |
Ide T, Takesue Y, Ikawa K, et al. Population pharmacokinetics/ pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2018, 51 (5): 745- 751.
doi: 10.1016/j.ijantimicag.2018.01.021 |
| 22 |
Xie F, Mantzarlis K, Malliotakis P, et al. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia[J]. J Antimicrob Chemother, 2019, 74 (3): 667- 674.
doi: 10.1093/jac/dky500 |
| 23 |
Dong H, Xie J, Wang T, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients[J]. Int J Antimicrob Agents, 2016, 48 (3): 259- 264.
doi: 10.1016/j.ijantimicag.2016.05.009 |
| 24 |
Wang D, Zheng X, Yang Y, et al. Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count[J]. Exp Ther Med, 2019, 18 (3): 1786- 1792.
doi: 10.3892/etm.2019.7747 |
| 25 |
Wang X, Wang Y, Yao F, et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically Ill patients: a multicenter, prospective, open-label, observational study[J]. Drug Des Devel Ther, 2021, 15, 2129- 2141.
doi: 10.2147/DDDT.S303497 |
| 26 |
Fang J, Zhang XS, Zhang CH, et al. Model based identification of linezolid exposure-toxicity thresholds in hospitalized patients[J]. Front Pharmacol, 2021, 12, 732503.
doi: 10.3389/fphar.2021.732503 |
| 27 |
Wicha SG, Mair A, Chiriac U, et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients[J]. Int J Antimicrob Agents, 2022, 59 (5): 106572.
doi: 10.1016/j.ijantimicag.2022.106572 |
| 28 |
Wu F, Zhang XS, Dai Y, et al. Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically Ill patients[J]. Front Pharmacol, 2022, 13, 844567.
doi: 10.3389/fphar.2022.844567 |
| 29 |
Bock M, VAN Hasselt JGC, Schwartz F, et al. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis[J]. J Antimicrob Chemother, 2023, 78 (12): 2840- 2848.
doi: 10.1093/jac/dkad316 |
| 30 |
Liu Q, Li S, Xie F. Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis[J]. Int J Antimicrob Agents, 2023, 62 (4): 106949.
doi: 10.1016/j.ijantimicag.2023.106949 |
| 31 |
Bock M, Theut AM, Van Hasselt JGC, et al. Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a POET substudy[J]. Clin Infect Dis, 2023, 77 (2): 242- 251.
doi: 10.1093/cid/ciad168 |
| 32 |
Li Y, Fang Q, Wu Z, et al. Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients[J]. Eur J Clin Pharmacol, 2024, 80 (9): 1295- 1304.
doi: 10.1007/s00228-024-03702-9 |
| 33 |
Xu J, Chen X, Zhang Q, et al. Population pharmacokinetic/pharmacodynamic study of linezolid in hospital-acquired pneumonia patients with renal insufficiency[J]. Drug Des Devel Ther, 2024, 18, 5073- 5086.
doi: 10.2147/DDDT.S474470 |
| 34 |
Milaković D, Kovačević T, Kovačević P, et al. Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-associated acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation-a step toward correct dosing[J]. Pharmaceutics, 2024, 16 (2): 418.
doi: 10.3390/pharmaceutics16020253 |
| 35 | Maha A, Ali M, Bilal H, et al. Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies[J]. Pak J Pharm Sci, 2025, 38 (1): 291- 298. |
| 36 |
Qin Y, Jiao Z, Ye YR, et al. External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients[J]. J Glob Antimicrob Resist, 2023, 35, 347- 353.
doi: 10.1016/j.jgar.2023.08.003 |
| 37 |
Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction[J]. Antimicrob Agents Chemother, 2003, 47 (9): 2775- 2780.
doi: 10.1128/AAC.47.9.2775-2780.2003 |
| 38 |
林忠, 谢群莉, 戴淑萍, 等. 中国成年患者利奈唑胺治疗群体药动学研究[J]. 中国临床药理学与治疗学, 2020, 25 (9): 992- 999.
doi: 10.12092/j.issn.1009-2501.2020.09.005 |
| 39 |
Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism[J]. J Clin Pharmacol, 2011, 51 (2): 229- 236.
doi: 10.1177/0091270010366445 |
| 40 |
Hashimoto S, Honda K, Fujita K, et al. Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies[J]. J Pharm Health Care Sci, 2018, 4, 27.
doi: 10.1186/s40780-018-0123-1 |
| 41 | Heffernan AJ, Mohd Sazlly Lim S, Lipman J, et al. A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients[J]. Anaesth Crit Care Pain Med, 2021, 40 (6): 100970. |
| 42 |
Mahmood I, Pettinato M. Impact of intrinsic and extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted?[J]. Antibodies (Basel), 2021, 11 (1): 2.
doi: 10.3390/antib11010002 |
| 43 |
肖莹, 张弋, 李淑娟, 等. 利奈唑胺在重症感染患者中的药动学[J]. 中国医院药学杂志, 2016, 36 (7): 535- 539.
doi: 10.13286/j.cnki.chinhosppharmacyj.2016.07.04 |
| 44 |
Figuera-Figuera A, Navarro J, Sabaté S, et al. SeDeM as a tool to validate drug substance manufacturing processes and assess scalability and suitability for direct compression: supplier screening[J]. Pharmaceutics, 2023, 15 (8): 2034.
doi: 10.3390/pharmaceutics15082034 |
| 45 |
Alihodzic D, Broeker A, Baehr M, et al. Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing[J]. Front Pharmacol, 2020, 11, 172.
doi: 10.3389/fphar.2020.00172 |
| 46 |
Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings[J]. Br J Clin Pharmacol, 2013, 75 (4): 1068- 1080.
doi: 10.1111/j.1365-2125.2012.04406.x |
| [1] | Shiya WU, Xiaodan LIU, Yan HU, Qi LIN. Correlation analysis between tigecycline therapeutic concentration monitoring and adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(9): 1238-1248. |
| [2] | Jianxin YANG, Yunli YU. Pharmacokinetic/pharmacodynamic characteristics of adalimumab in moderate-to-severe psoriasis and its therapeutic drug monitoring applications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 921-927. |
| [3] | CHEN Bing, ZUO Xiaocong, LI Xingang, SHANG Dewei, ZHOU Peijun, DING Junjie, XIANG Xiaoqiang, QIU Xiaoyan, WANG Zhuo, LI Xiaoyu, ZHANG Yi, ZHAO Wei, WANG Yuzhu, GAO Jianjun, JIAO Zheng. Expert consensus on the model informed precision dosing of tacrolimus in patients receiving anti-rejection therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 433-445. |
| [4] | WANG Xuebin, GAO Lihong, ZHANG Lingpeng, YANG Yunyun, LIU Hongxia, WANG Zhuo, SUN Huajun. Study on the intervention and evaluation for the abnormal results of tacrolimus therapeutic drug monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1322-1328. |
| [5] | YUAN Shixuan, LV Ziyan, YANG Yong, CHEN Lu, ZHANG Lijuan. Clinical study on model-guided vancomycin plasma concentration monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1344-1352. |
| [6] | DAI Youai, ZHU Kouzhu, WANG Yan, LU Zhou, DING Xiaoliang, WANG Lei. Determination of secukinumab in human plasma by ELISA method and application in psoriasis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(11): 1267-1271. |
| [7] | XIAO Lei, CAO Can, LIU Jiatao. Analysis of the concentration of digoxin and influential factors for adverse reaction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(11): 1280-1287. |
| [8] | WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145. |
| [9] | HE Jie, LIU Dongxue, ZHONG Lingjun, SHAO Hua, HU Linlin. Establishment of a limited sampling strategy to estimate micafungin exposure in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1264-1271. |
| [10] | PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646. |
| [11] | ZHANG Siliang, HU Linlin, SHAO Hua, CHEN Xijing. Research progress on the influence of sex differences on the action of psychotropic drugs#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 324-331. |
| [12] | LIN Zhong, XIE Qunli, DAI Shuping, CHEN Jing, LIN Feiyang, ZHU Yanwu, YU Guoliang, ZHANG Yuanhuai, CUI Ke. Population pharmacokinetics of Linezolid in Chinese adult infection patients#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 992-999. |
| [13] | ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575. |
| [14] | . Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413. |
| [15] | DING Zhirong, CAI Xiaozhen, ZENG Haiwen, LIN Tianlai. Population pharmacokinetics of vancomycin in post-operative neurosurgical patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1252-1257. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||